BeiGene Capex To Revenue vs Capex To Depreciation Analysis

BGNE Stock

USD 190.30 0.21 0.11%

BeiGene financial indicator trend analysis is way more than just evaluating BeiGene prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BeiGene is a good investment. Please check the relationship between BeiGene Capex To Revenue and its Capex To Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.

Capex To Revenue vs Capex To Depreciation

Capex To Revenue vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BeiGene Capex To Revenue account and Capex To Depreciation. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between BeiGene's Capex To Revenue and Capex To Depreciation is 0.41. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of BeiGene, assuming nothing else is changed. The correlation between historical values of BeiGene's Capex To Revenue and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of BeiGene are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Capex To Revenue i.e., BeiGene's Capex To Revenue and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

0.41

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from BeiGene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BeiGene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.At present, BeiGene's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 17.4 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.84.

	2021	2022	2023	2024 (projected)
Interest Expense	15.8M	52.5M	37.4M	39.2M
Depreciation And Amortization	46.5M	66.3M	87.7M	92.1M

Interest Expense Depreciation And Amortization

BeiGene fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.86	0.88	0.85	1.0	0.95	0.94	0.71	0.68	-0.92	-0.82	0.81	0.92	0.77	-0.18	0.65	0.77	0.99	0.87	0.9	0.65	0.94	0.89	0.9	0.92	0.71
Short Long Term Debt Total	0.86		0.98	0.96	0.83	0.86	0.95	0.96	0.41	-0.89	-0.99	0.98	0.94	0.96	-0.19	0.32	0.73	0.8	0.96	0.89	0.32	0.84	0.99	0.99	0.97	0.96
Other Current Liab	0.88	0.98		0.99	0.86	0.92	0.98	0.95	0.43	-0.91	-0.97	0.93	0.95	0.97	-0.05	0.45	0.68	0.84	0.94	0.87	0.37	0.8	0.97	0.99	0.99	0.94
Total Current Liabilities	0.85	0.96	0.99		0.83	0.91	0.97	0.95	0.38	-0.88	-0.95	0.92	0.92	0.98	0.05	0.42	0.65	0.8	0.93	0.84	0.36	0.75	0.94	0.97	0.98	0.94
Total Stockholder Equity	1.0	0.83	0.86	0.83		0.95	0.93	0.68	0.7	-0.92	-0.79	0.78	0.91	0.74	-0.19	0.68	0.76	0.99	0.85	0.88	0.68	0.94	0.88	0.89	0.9	0.68
Other Liab	0.95	0.86	0.92	0.91	0.95		0.96	0.75	0.64	-0.87	-0.82	0.81	0.89	0.81	0.01	0.63	0.68	0.95	0.87	0.84	0.69	0.86	0.87	0.9	0.94	0.73
Net Tangible Assets	0.94	0.95	0.98	0.97	0.93	0.96		0.88	0.52	-0.94	-0.93	0.91	0.96	0.92	-0.06	0.55	0.73	0.92	0.95	0.88	0.5	0.86	0.97	0.98	0.99	0.87
Property Plant And Equipment Net	0.71	0.96	0.95	0.95	0.68	0.75	0.88		0.2	-0.8	-0.97	0.94	0.86	0.99	-0.04	0.19	0.62	0.63	0.91	0.79	0.1	0.65	0.93	0.93	0.91	1.0
Current Deferred Revenue	0.68	0.41	0.43	0.38	0.7	0.64	0.52	0.2		-0.51	-0.36	0.4	0.49	0.29	-0.21	0.58	0.66	0.73	0.48	0.54	0.74	0.75	0.46	0.47	0.5	0.2
Net Debt	-0.92	-0.89	-0.91	-0.88	-0.92	-0.87	-0.94	-0.8	-0.51		0.88	-0.8	-0.99	-0.83	0.27	-0.67	-0.65	-0.89	-0.85	-0.87	-0.37	-0.87	-0.94	-0.93	-0.92	-0.82
Retained Earnings	-0.82	-0.99	-0.97	-0.95	-0.79	-0.82	-0.93	-0.97	-0.36	0.88		-0.97	-0.93	-0.96	0.22	-0.28	-0.68	-0.76	-0.93	-0.88	-0.22	-0.8	-0.98	-0.98	-0.96	-0.98
Accounts Payable	0.81	0.98	0.93	0.92	0.78	0.81	0.91	0.94	0.4	-0.8	-0.97		0.86	0.94	-0.18	0.17	0.78	0.75	0.96	0.85	0.34	0.81	0.95	0.95	0.93	0.93
Cash	0.92	0.94	0.95	0.92	0.91	0.89	0.96	0.86	0.49	-0.99	-0.93	0.86		0.89	-0.25	0.59	0.68	0.88	0.9	0.88	0.35	0.87	0.97	0.97	0.96	0.88
Non Current Assets Total	0.77	0.96	0.97	0.98	0.74	0.81	0.92	0.99	0.29	-0.83	-0.96	0.94	0.89		0.04	0.29	0.67	0.7	0.93	0.8	0.21	0.69	0.94	0.95	0.94	0.98
Non Currrent Assets Other	-0.18	-0.19	-0.05	0.05	-0.19	0.01	-0.06	-0.04	-0.21	0.27	0.22	-0.18	-0.25	0.04		0.07	-0.1	-0.18	-0.07	-0.31	0.08	-0.41	-0.24	-0.18	-0.09	-0.12
Other Assets	0.65	0.32	0.45	0.42	0.68	0.63	0.55	0.19	0.58	-0.67	-0.28	0.17	0.59	0.29	0.07		0.32	0.69	0.34	0.41	0.5	0.52	0.42	0.43	0.47	0.2
Long Term Debt	0.77	0.73	0.68	0.65	0.76	0.68	0.73	0.62	0.66	-0.65	-0.68	0.78	0.68	0.67	-0.1	0.32		0.74	0.83	0.7	0.51	0.82	0.76	0.73	0.72	0.6
Cash And Short Term Investments	0.99	0.8	0.84	0.8	0.99	0.95	0.92	0.63	0.73	-0.89	-0.76	0.75	0.88	0.7	-0.18	0.69	0.74		0.83	0.85	0.74	0.94	0.85	0.86	0.88	0.63
Common Stock Total Equity	0.87	0.96	0.94	0.93	0.85	0.87	0.95	0.91	0.48	-0.85	-0.93	0.96	0.9	0.93	-0.07	0.34	0.83	0.83		0.83	0.43	0.84	0.96	0.96	0.96	0.89
Common Stock Shares Outstanding	0.9	0.89	0.87	0.84	0.88	0.84	0.88	0.79	0.54	-0.87	-0.88	0.85	0.88	0.8	-0.31	0.41	0.7	0.85	0.83		0.42	0.88	0.89	0.9	0.88	0.8
Short Term Investments	0.65	0.32	0.37	0.36	0.68	0.69	0.5	0.1	0.74	-0.37	-0.22	0.34	0.35	0.21	0.08	0.5	0.51	0.74	0.43	0.42		0.63	0.34	0.38	0.45	0.07
Non Current Liabilities Total	0.94	0.84	0.8	0.75	0.94	0.86	0.86	0.65	0.75	-0.87	-0.8	0.81	0.87	0.69	-0.41	0.52	0.82	0.94	0.84	0.88	0.63		0.88	0.87	0.86	0.67
Other Current Assets	0.89	0.99	0.97	0.94	0.88	0.87	0.97	0.93	0.46	-0.94	-0.98	0.95	0.97	0.94	-0.24	0.42	0.76	0.85	0.96	0.89	0.34	0.88		0.99	0.97	0.93
Other Stockholder Equity	0.9	0.99	0.99	0.97	0.89	0.9	0.98	0.93	0.47	-0.93	-0.98	0.95	0.97	0.95	-0.18	0.43	0.73	0.86	0.96	0.9	0.38	0.87	0.99		0.99	0.94
Total Liab	0.92	0.97	0.99	0.98	0.9	0.94	0.99	0.91	0.5	-0.92	-0.96	0.93	0.96	0.94	-0.09	0.47	0.72	0.88	0.96	0.88	0.45	0.86	0.97	0.99		0.91
Property Plant And Equipment Gross	0.71	0.96	0.94	0.94	0.68	0.73	0.87	1.0	0.2	-0.82	-0.98	0.93	0.88	0.98	-0.12	0.2	0.6	0.63	0.89	0.8	0.07	0.67	0.93	0.94	0.91

Click cells to compare fundamentals

BeiGene Account Relationship Matchups

BeiGene fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.6B	5.6B	8.6B	6.4B	5.8B	3.2B
Short Long Term Debt Total	277.3M	562.0M	694.6M	891.1M	930.2M	976.7M
Other Current Liab	152.7M	445.7M	705.6M	538.8M	739.8M	776.8M
Total Current Liabilities	286.0M	1.1B	1.6B	1.0B	1.8B	1.9B
Total Stockholder Equity	978.4M	3.9B	6.2B	4.4B	3.5B	2.2B
Other Liab	57.1M	443.3M	562.5M	283.7M	326.3M	342.6M
Net Tangible Assets	956.3M	3.9B	6.2B	4.3B	5.0B	5.2B
Property Plant And Equipment Net	313.1M	446.3M	686.7M	845.9M	1.4B	1.5B
Net Debt	(340.7M)	(820.0M)	(3.7B)	(3.0B)	(2.2B)	(2.1B)
Retained Earnings	(2.0B)	(3.6B)	(5.0B)	(7.1B)	(8.0B)	(7.6B)
Accounts Payable	122.5M	232.0M	168.0M	294.8M	315.1M	330.9M
Cash	618.0M	1.4B	4.4B	3.9B	3.2B	3.3B
Non Current Assets Total	439.6M	640.1M	1.0B	845.9M	1.6B	1.7B
Non Currrent Assets Other	2.5M	24.6M	30.7M	(186.5M)	35.7M	37.5M
Other Assets	108.7M	186.8M	8.6B	819.9M	2.0	1.9
Long Term Debt	240.7M	183.6M	202.1M	209.1M	197.6M	143.1M
Cash And Short Term Investments	985.5M	4.7B	6.6B	4.5B	3.2B	2.3B
Common Stock Total Equity	77K	79K	118K	133K	153.0K	160.6K
Common Stock Shares Outstanding	60.1M	83.5M	92.8M	103.1M	104.4M	72.1M
Short Term Investments	364.7M	3.3B	2.2B	665.3M	2.6M	2.5M
Liabilities And Stockholders Equity	1.6B	5.6B	8.6B	6.4B	5.8B	3.2B
Non Current Liabilities Total	347.9M	656.3M	803.4M	977.9M	457.8M	376.4M
Other Current Assets	85.8M	141.0M	253.1M	288.2M	262.3M	275.4M
Other Stockholder Equity	2.9B	7.4B	11.2B	11.5B	11.6B	12.2B
Total Liab	633.9M	1.7B	2.4B	2.0B	2.3B	2.4B
Property Plant And Equipment Gross	324.9M	399.5M	811.0M	1.1B	1.6B	1.7B
Total Current Assets	1.2B	5.0B	7.6B	4.7B	4.2B	2.6B
Accumulated Other Comprehensive Income	(8.0M)	6.9M	18.0M	(77.4M)	(99.4M)	(94.5M)
Short Term Debt	10.8M	362.8M	471.4M	377.1M	732.3M	768.9M
Common Stock	79K	118K	133K	135K	155.3K	83.2K
Property Plant Equipment	324.9M	357.7M	587.6M	955.9M	1.1B	1.2B
Deferred Long Term Liab	11.1M	10.5M	10.8M	14.2M	16.3M	10.1M
Long Term Debt Total	189.7M	240.7M	183.6M	202.1M	232.4M	156.4M
Capital Surpluse	2.7B	2.9B	7.4B	11.2B	12.9B	13.5B
Net Receivables	72.8M	79.7M	500.2M	173.2M	395.9M	415.7M
Retained Earnings Total Equity	(1.0B)	(2.0B)	(3.6B)	(5.0B)	(4.5B)	(4.2B)
Inventory	28.6M	89.3M	242.6M	282.3M	416.1M	436.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:

How To Invest In BeiGene

Details

Is BeiGene Stock a good investment?

Details

What is BeiGene's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(8.18)

Revenue Per Share

225.239

Quarterly Revenue Growth

0.395

Return On Assets

(0.1)

Return On Equity

(0.23)

The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BeiGene Capex To Revenue vs Capex To Depreciation Analysis

Capex To Revenue vs Capex To Depreciation

Capex To Revenue vs Capex To Depreciation Correlation Analysis

Correlation Coefficient

Capex To Revenue

Capex To Depreciation

BeiGene fundamental ratios Correlations

BeiGene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BeiGene fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Short Long Term Debt Total
Other Stockholder Equity	+ 0.99	Short Long Term Debt Total
Total Current Liabilities	+ 0.99	Other Current Liab

Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Other Current Assets	- 0.98	Retained Earnings
Accounts Payable	- 0.97	Retained Earnings